Lilly Gets EUA For Antibody Cocktail It Says Might Target Variants

FDA on Tuesday night (Feb. 9) granted emergency use authorization for a combination of monoclonal antibodies from Eli Lilly, bamlanivimab and etesevimab, to treat patients who experience mild to moderate COVID-19 symptoms and are at risk of severe adverse health effects or hospitalization. Though FDA’s EUA does not say whether the combination therapy could be used for variant strains of the SARS-CoV-2 virus, Lilly says it believes the combination therapy could eventually prove to be beneficial against emerging variants. The...